These clinical cases provide initial evidence of the promising clinical activity with manageable toxicity of exarafenib in BRAF-mutant NSCLC patients with unmet clinical need, consistent with our supporting preclinical dataset. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.